Our Technology 

​​​​NucleoBio's scientists are pioneers in molecular biology research and the in-depth study of DNA.  It was this research that led to the discovery of the multiplexing of PVT1 exons 4A, 4B, and 9, and the development of our Prostac® diagnostic test.​​​​​​​​​​

​

Specifically, Prostac® is a Nucleic acid amplification test (qRT-PCR) that uses PVT1 primers to quantify the concentration (in copies/µL) of the specific prostate cancer biomarkers. Leveraging generative Artificial Intelligence, NucleoBio uses a computational algorithm incorporating copies / uL of  PVT1 exons 4A, 4B, and 9 to compute a Prostac® Score.  With this score, Prostac® can distinguish between indolent and aggressive prostate cancer and identify the risk group (i.e. stratification).

​​

The accuracy, sensitivity, specificity and predictive values of Prostac® have been peer reviewed. In the future, generative AI will aid faster and more accurate computation, and subsequent interpretation.

​

​​​​We are developing a family of proprietary, molecular-based tests that will enable the early detection of additional cancers with same unparalleled precision that can empower physicians to prescribe data-driven and personalized life-saving interventions.